Trial Profile

A Randomized Controlled Phase IIa, Two-arm Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients With Post-COVID Syndrome

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allogeneic human umbilical cord blood haematopoietic progenitor cell therapy-StemCyte (Primary)
Indications Post acute COVID 19 syndrome
Focus Adverse reactions
Sponsors StemCyte

Most Recent Events

24 Mar 2025 Status changed from active, no longer recruiting to completed.
19 Dec 2024 According to a StemCyte media release, Building on these positive results, StemCyte is preparing to accelerate the development of REGENECYTE and is in rolling discussions with the FDA to move forward with the next phase of clinical trials.
19 Dec 2024 Results presented in the StemCyte Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com